GeneDx (WGSWW) Financials

$0.07 +0.02 (+38.57%)

As of 05/23/2025 03:58 PM Eastern

Annual Income Statements for GeneDx

This table shows GeneDx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Income / (Loss) Attributable to Common Shareholders	-52	-176	-549	-245	-241	-33
Consolidated Net Income / (Loss)	-52	-176	-549	-245	-241	-30
Net Income / (Loss) Continuing Operations	-52	-176	-549	-245	-241	-30
Total Pre-Tax Income	-53	-177	-598	-245	-241	-30
Total Operating Income	-23	-181	-668	-446	-242	-30
Total Gross Profit	194	90	-27	-17	4.03	83
Total Revenue	305	203	235	212	179	196
Operating Revenue	305	203	235	212	179	196
Total Cost of Revenue	111	113	261	229	175	113
Operating Cost of Revenue	111	113	261	229	175	113
Total Operating Expenses	218	271	641	430	246	113
Selling, General & Admin Expense	101	134	216	206	101	29
Marketing Expense	67	61	122	113	63	39
Research & Development Expense	46	58	86	105	73	35
Other Operating Expenses / (Income)	3.41	7.22	6.31	5.66	9.40	9.45
Impairment Charge	0.00	10	210	0.00	0.00	-
Total Other Income / (Expense), net	-29	2.73	70	201	0.65	0.71
Interest & Investment Income	-3.03	1.11	-	0.08	0.51	0.99
Other Income / (Expense), net	-26	1.62	70	204	2.62	0.50
Income Tax Expense	-0.34	-0.93	-49	0.00	0.00	0.00
Basic Earnings per Share	($1.94)	($7.23)	($53.63)	($2.27)	($47,036.00)	($264,056.00)
Weighted Average Basic Shares Outstanding	26.89M	24.31M	10.24M	108.08M	5.13K	124.00
Diluted Earnings per Share	($1.94)	($7.23)	($53.63)	($2.27)	($47,036.00)	($264,056.00)
Weighted Average Diluted Shares Outstanding	26.89M	24.31M	10.24M	108.08M	5.13K	124.00
Weighted Average Basic & Diluted Shares Outstanding	28.07M	26.05M	798.25M	244.96M	-	-

This table shows GeneDx's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-6.53	5.44	-8.31	-29	-20	-26	-42	-47	-61	-309	-78
Consolidated Net Income / (Loss)	-6.53	5.44	-8.31	-29	-20	-26	-42	-47	-61	-309	-78
Net Income / (Loss) Continuing Operations	-6.53	5.44	-8.31	-29	-20	-26	-42	-47	-61	-309	-78
Total Pre-Tax Income	-6.08	5.41	-8.36	-29	-20	-26	-42	-47	-61	-309	-78
Total Operating Income	-4.55	8.81	-7.78	-11	-14	-26	-43	-52	-60	-325	-91
Total Gross Profit	58	66	48	43	37	31	25	19	15	-16	14
Total Revenue	87	96	77	71	62	57	53	49	43	61	83
Operating Revenue	87	96	77	71	62	57	53	49	43	61	83
Total Cost of Revenue	29	29	29	28	25	27	28	30	28	78	70
Operating Cost of Revenue	29	29	29	28	25	27	28	30	28	78	70
Total Operating Expenses	63	57	56	54	51	56	68	70	76	309	104
Selling, General & Admin Expense	32	27	26	25	22	27	26	37	44	43	55
Marketing Expense	18	18	17	17	16	16	17	15	13	29	34
Research & Development Expense	13	12	12	11	12	12	14	17	15	24	13
Total Other Income / (Expense), net	-1.53	-3.39	-0.58	-19	-6.66	-1.71	0.51	4.71	-0.77	16	13
Interest & Investment Income	-0.64	-	-0.84	-0.89	-	-	1.05	1.07	-	-	-
Other Income / (Expense), net	-0.89	-2.69	0.26	-18	-6.06	-0.73	-0.54	3.63	-0.74	16	13
Income Tax Expense	0.45	-0.02	-0.05	-0.19	-0.08	-0.41	-0.17	-0.20	-0.15	0.09	-0.07
Basic Earnings per Share	($0.23)	$0.20	($0.31)	($1.10)	($0.78)	($1.06)	($1.64)	($1.84)	($3.04)	($30.16)	($6.72)
Weighted Average Basic Shares Outstanding	28.15M	26.89M	27.10M	26.62M	26.06M	24.31M	25.79M	25.42M	20.06M	10.24M	11.54M
Diluted Earnings per Share	($0.23)	$0.20	($0.31)	($1.10)	($0.78)	($1.06)	($1.64)	($1.84)	($3.04)	($30.16)	($6.72)
Weighted Average Diluted Shares Outstanding	28.15M	26.89M	27.10M	26.62M	26.06M	24.31M	25.79M	25.42M	20.06M	10.24M	11.54M
Weighted Average Basic & Diluted Shares Outstanding	28.53M	28.07M	27.47M	26.94M	26.14M	26.05M	25.88M	25.77M	25.59M	798.25M	386.80M

This table details how cash moves in and out of GeneDx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Change in Cash & Equivalents	-14	-38	-263	283	3.95	114
Net Cash From Operating Activities	-28	-180	-319	-190	-93	-19
Net Cash From Continuing Operating Activities	-29	-180	-319	-192	-93	-19
Net Income / (Loss) Continuing Operations	-52	-176	-549	-245	-241	-30
Consolidated Net Income / (Loss)	-52	-176	-549	-245	-241	-30
Depreciation Expense	22	34	59	22	12	6.41
Non-Cash Adjustments To Reconcile Net Income	23	-1.35	183	25	123	6.73
Changes in Operating Assets and Liabilities, net	-21	-37	-13	6.65	14	-2.16
Net Cash From Investing Activities	-30	-44	-141	-21	-32	-15
Net Cash From Continuing Investing Activities	-30	-44	-141	-21	-32	-15
Purchase of Property, Plant & Equipment	-5.49	-5.71	-14	-21	-32	-15
Acquisitions	0.00	-12	-127	0.00	0.00	-
Purchase of Investments	-66	-48	0.00	-	-	-
Sale of Property, Plant & Equipment	0.00	4.03	0.00	-	-	-
Sale and/or Maturity of Investments	42	18	0.00	-	-	-
Net Cash From Financing Activities	44	186	197	494	129	148
Net Cash From Continuing Financing Activities	44	186	197	498	129	148
Repayment of Debt	-0.50	-2.00	0.00	-10	-0.19	-1.71
Issuance of Debt	0.00	49	0.00	0.00	16	0.00
Issuance of Common Equity	47	143	198	793	0.00	0.00
Other Financing Activities, net	-2.33	-3.31	-0.34	-2.46	-4.01	31
Cash Interest Paid	6.68	3.04	1.93	2.75	1.75	0.31
Cash Income Taxes Paid	1.17	1.47	1.24	0.35	0.00	0.00

This table details how cash moves in and out of GeneDx's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	14	27	1.82	-28	-16	12	-69	-57	77	-67	-93
Net Cash From Operating Activities	10	-3.18	-4.40	-4.51	-16	-30	-41	-54	-56	-65	-88
Net Cash From Continuing Operating Activities	10	-3.45	-4.40	-4.51	-16	-30	-41	-54	-56	-65	-88
Net Income / (Loss) Continuing Operations	-6.53	5.44	-8.31	-29	-20	-26	-42	-47	-61	-309	-78
Consolidated Net Income / (Loss)	-6.53	5.44	-8.31	-29	-20	-26	-42	-47	-61	-309	-78
Depreciation Expense	5.68	5.56	5.93	5.22	5.25	6.09	8.67	10	8.64	34	11
Non-Cash Adjustments To Reconcile Net Income	6.48	-7.99	2.89	22	5.50	-2.74	6.60	-7.01	1.80	194	-8.74
Changes in Operating Assets and Liabilities, net	4.56	-6.45	-4.90	-2.85	-6.92	-7.44	-14	-10	-5.01	16	-13
Net Cash From Investing Activities	-9.41	-0.52	-7.76	-23	0.84	-4.86	-27	-11	-0.46	-2.84	-4.28
Net Cash From Continuing Investing Activities	-9.41	-0.52	-7.76	-23	0.84	-4.86	-27	-11	-0.46	-2.84	-4.28
Purchase of Property, Plant & Equipment	-6.13	-3.05	-0.65	-1.35	-0.44	-2.38	-0.11	-2.76	-0.46	-2.84	-4.28
Purchase of Investments	-17	-14	-23	-24	-5.17	-3.74	-44	-	0.00	-	-
Sale and/or Maturity of Investments	14	16	16	2.87	6.45	1.10	17	-	0.00	-	-
Net Cash From Financing Activities	14	31	14	-0.39	-0.44	47	-0.91	7.39	133	0.07	-0.65
Net Cash From Continuing Financing Activities	14	31	14	-0.39	-0.44	47	-0.91	7.39	133	0.07	-0.65
Repayment of Debt	-0.30	-0.30	-0.20	-	0.00	-	-	-	-2.00	-	-
Issuance of Common Equity	14	32	15	-	0.00	-	-	7.56	135	-	-0.05
Other Financing Activities, net	0.12	-1.08	-0.42	-0.39	-0.44	-1.45	-0.91	-0.18	-0.78	0.07	-0.59
Cash Interest Paid	1.60	0.61	2.04	2.01	2.02	1.93	0.17	0.36	0.58	0.14	0.60
Cash Income Taxes Paid	0.21	0.26	0.35	0.26	0.30	0.29	0.18	0.90	0.10	0.75	0.12

This table presents GeneDx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Total Assets	419	419	491	554	252
Total Current Assets	198	182	213	484	174
Cash & Equivalents	85	100	124	401	108
Short-Term Investments	56	30	0.00	-	-
Accounts Receivable	38	33	43	27	32
Inventories, net	11	8.78	14	33	25
Prepaid Expenses	8.50	11	32	19	4.56
Plant, Property, & Equipment, net	33	32	52	63	63
Total Noncurrent Assets	189	204	227	7.83	14
Intangible Assets	159	173	187	0.00	-
Other Noncurrent Operating Assets	30	31	40	7.83	14
Total Liabilities & Shareholders' Equity	419	419	491	554	252
Total Liabilities	174	191	237	166	247
Total Current Liabilities	55	59	144	101	73
Accounts Payable	30	37	85	47	28
Other Current Liabilities	25	21	59	34	30
Total Noncurrent Liabilities	119	132	93	65	174
Long-Term Debt	52	53	6.25	11	19
Capital Lease Obligations	61	63	60	0.00	21
Noncurrent Deferred & Payable Income Tax Liabilities	0.97	1.56	2.66	0.00	-
Other Noncurrent Operating Liabilities	5.52	15	24	54	2.07
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	245	228	254	388	-330
Total Preferred & Common Equity	245	228	254	388	-330
Preferred Stock	0.00	0.00	0.00	0.00	0.00
Total Common Equity	245	228	254	388	-330
Common Stock	1,597	1,528	1,378	964	0.00
Retained Earnings	-1,352	-1,300	-1,124	-575	-330
Accumulated Other Comprehensive Income / (Loss)	0.83	0.43	0.00	-	-

This table presents GeneDx's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	446	409	389	395	417	476	545	829
Total Current Assets	226	186	162	163	172	213	272	307
Cash & Equivalents	100	58	56	84	87	157	202	191
Short-Term Investments	59	59	51	29	27	-	-	-
Accounts Receivable	46	38	26	29	32	34	34	44
Inventories, net	13	11	10	12	9.35	12	12	44
Prepaid Expenses	8.01	20	19	9.97	16	11	12	18
Plant, Property, & Equipment, net	36	31	31	31	36	43	50	84
Total Noncurrent Assets	184	191	196	200	210	220	223	438
Intangible Assets	155	162	166	169	176	180	183	190
Other Noncurrent Operating Assets	29	29	30	31	34	40	40	66
Total Liabilities & Shareholders' Equity	446	409	389	395	417	476	545	829
Total Liabilities	189	204	195	187	163	180	217	268
Total Current Liabilities	70	77	68	51	68	84	119	162
Accounts Payable	42	56	52	32	39	55	74	89
Other Current Liabilities	28	21	16	18	29	30	45	74
Total Noncurrent Liabilities	119	127	127	137	95	96	98	105
Long-Term Debt	52	52	52	52	6.05	6.25	6.25	11
Capital Lease Obligations	60	60	61	62	64	64	64	62
Noncurrent Deferred & Payable Income Tax Liabilities	1.15	1.05	1.17	1.42	2.06	2.25	2.51	2.60
Other Noncurrent Operating Liabilities	6.62	14	13	21	23	24	25	30
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	257	205	194	207	254	296	328	561
Total Preferred & Common Equity	257	205	194	207	254	296	328	561
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	257	205	194	207	254	296	328	561
Common Stock	1,616	1,561	1,543	1,527	1,529	1,528	1,514	1,377
Retained Earnings	-1,359	-1,358	-1,350	-1,320	-1,274	-1,232	-1,185	-816
Accumulated Other Comprehensive Income / (Loss)	0.91	0.92	0.46	0.29	-	-	-	-

This table displays calculated financial ratios and metrics derived from GeneDx's official financial filings.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Growth Metrics	-	-	-	-	-	-
Revenue Growth	50.79%	-13.69%	10.60%	18.33%	-8.59%	0.00%
EBITDA Growth	80.97%	73.01%	-143.73%	3.02%	-868.59%	0.00%
EBIT Growth	72.29%	70.04%	-146.20%	-1.36%	-700.33%	0.00%
NOPAT Growth	87.15%	72.95%	-49.65%	-84.36%	-695.69%	0.00%
Net Income Growth	70.25%	67.98%	-123.72%	-1.68%	-712.48%	0.00%
EPS Growth	73.17%	86.52%	-123.72%	100.00%	82.19%	0.00%
Operating Cash Flow Growth	84.18%	43.56%	-67.59%	-104.49%	-397.27%	0.00%
Free Cash Flow Firm Growth	86.34%	78.36%	-79.05%	-240.96%	0.00%	0.00%
Invested Capital Growth	1.59%	8.91%	13,472.10%	97.58%	0.00%	0.00%
Revenue Q/Q Growth	14.30%	-1.90%	1.54%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	52.69%	63.68%	-81.56%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	38.70%	61.23%	-82.20%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	59.74%	62.36%	-45.60%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	37.38%	61.69%	-95.78%	0.00%	0.00%	0.00%
EPS Q/Q Growth	37.01%	59.36%	-95.78%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	48.35%	16.19%	-4.13%	-21.46%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	36.43%	-39.87%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	8.21%	1.71%	-55.74%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	63.64%	44.43%	-11.40%	-7.82%	2.25%	42.20%
EBITDA Margin	-9.05%	-71.70%	-229.26%	-104.04%	-126.94%	-11.98%
Operating Margin	-7.60%	-89.15%	-284.48%	-210.25%	-134.95%	-15.50%
EBIT Margin	-16.24%	-88.35%	-254.53%	-114.34%	-133.49%	-15.25%
Profit (Net Income) Margin	-17.12%	-86.77%	-233.91%	-115.64%	-134.58%	-15.14%
Tax Burden Percent	99.35%	99.48%	91.80%	100.00%	100.00%	100.00%
Interest Burden Percent	106.11%	98.72%	100.11%	101.14%	100.82%	99.31%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-7.55%	-61.74%	-480.40%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	160.55%	74.98%	-443.90%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-14.55%	-11.24%	309.33%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-22.10%	-72.97%	-171.07%	-125.04%	-5,500.00%	0.00%
Cash Return on Invested Capital (CROIC)	-9.13%	-70.26%	-339.15%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-11.84%	-39.35%	-114.32%	-60.23%	-95.12%	0.00%
Return on Assets (ROA)	-12.48%	-38.64%	-105.06%	-60.91%	-95.91%	0.00%
Return on Common Equity (ROCE)	-22.10%	-72.97%	-171.07%	-18.49%	413,692.00%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-21.32%	-77.09%	-216.39%	-63.23%	73.12%	0.00%
Net Operating Profit after Tax (NOPAT)	-16	-126	-467	-312	-169	-21
NOPAT Margin	-5.32%	-62.41%	-199.13%	-147.18%	-94.46%	-10.85%
Net Nonoperating Expense Percent (NNEP)	-168.10%	-136.72%	-36.50%	29.45%	-221.79%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-4.54%	-36.79%	-	-	-	-
Cost of Revenue to Revenue	36.36%	55.57%	111.40%	107.82%	97.75%	57.80%
SG&A Expenses to Revenue	33.10%	66.03%	92.11%	97.07%	56.18%	15.03%
R&D to Revenue	14.97%	28.76%	36.73%	49.56%	40.54%	17.80%
Operating Expenses to Revenue	71.24%	133.59%	273.08%	202.43%	137.19%	57.70%
Earnings before Interest and Taxes (EBIT)	-50	-179	-597	-243	-239	-30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-28	-145	-538	-221	-228	-24
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	8.61	0.31	0.40	2.77	0.00	0.00
Price to Tangible Book Value (P/TBV)	24.37	1.29	1.52	2.77	0.00	0.00
Price to Revenue (P/Rev)	6.91	0.35	0.43	5.07	3.41	1.96
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	9.60	0.27	0.23	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	6.82	0.28	0.19	3.24	4.91	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.46	0.51	0.26	0.03	9.86	0.00
Long-Term Debt to Equity	0.46	0.51	0.26	0.03	9.06	0.00
Financial Leverage	-0.09	-0.15	-0.70	-1.16	-14.79	0.00
Leverage Ratio	1.77	1.89	1.63	2.05	57.35	0.00
Compound Leverage Factor	1.88	1.86	1.63	2.08	57.82	0.00
Debt to Total Capital	31.51%	33.65%	20.71%	2.76%	90.79%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	7.36%	0.00%
Long-Term Debt to Total Capital	31.51%	33.65%	20.71%	2.76%	83.43%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	701.97%	0.00%
Common Equity to Total Capital	68.49%	66.35%	79.29%	97.24%	-692.76%	0.00%
Debt to EBITDA	-4.08	-0.80	-0.12	-0.05	-0.19	0.00
Net Debt to EBITDA	1.03	0.10	0.11	1.76	0.29	0.00
Long-Term Debt to EBITDA	-4.08	-0.80	-0.12	-0.05	-0.17	0.00
Debt to NOPAT	-6.94	-0.91	-0.14	-0.04	-0.26	0.00
Net Debt to NOPAT	1.74	0.11	0.12	1.25	0.38	0.00
Long-Term Debt to NOPAT	-6.94	-0.91	-0.14	-0.04	-0.23	0.00
Altman Z-Score	3.51	-4.70	-6.32	2.20	-2.30	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	85.21%	7,621.67%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	3.61	3.10	1.47	4.77	2.37	0.00
Quick Ratio	3.26	2.77	1.16	4.22	1.91	0.00
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-20	-144	-665	-371	-109	0.00
Operating Cash Flow to CapEx	-518.96%	-10,742.22%	-2,228.42%	-916.16%	-291.26%	-121.17%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-998.28	-130.98	-44.02	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	-479.21	-67.17	-37.64	-23.92
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-500.72	-74.50	-50.57	-43.66
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.73	0.45	0.45	0.53	0.71	0.00
Accounts Receivable Turnover	8.67	5.32	6.71	7.21	5.55	0.00
Inventory Turnover	11.43	10.03	11.10	7.83	7.02	0.00
Fixed Asset Turnover	9.35	4.82	4.11	3.37	2.84	0.00
Accounts Payable Turnover	3.29	1.84	3.96	6.06	6.22	0.00
Days Sales Outstanding (DSO)	42.09	68.61	54.36	50.65	65.81	0.00
Days Inventory Outstanding (DIO)	31.93	36.39	32.89	46.60	51.98	0.00
Days Payable Outstanding (DPO)	110.93	198.35	92.28	60.21	58.64	0.00
Cash Conversion Cycle (CCC)	-36.91	-93.35	-5.03	37.05	59.15	0.00
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	217	213	196	-1.47	-60	0.00
Invested Capital Turnover	1.42	0.99	2.41	-6.85	-5.93	0.00
Increase / (Decrease) in Invested Capital	3.40	17	198	59	-60	0.00
Enterprise Value (EV)	2,083	57	44	686	881	0.00
Market Capitalization	2,111	71	102	1,076	611	385
Book Value per Share	$8.93	$8.81	$0.66	$1.61	($5.96)	$0.00
Tangible Book Value per Share	$3.15	$2.14	$0.17	$1.61	($5.96)	$0.00
Total Capital	358	344	320	399	48	0.00
Total Debt	113	116	66	11	43	0.00
Total Long-Term Debt	113	116	66	11	40	0.00
Net Debt	-28	-15	-58	-390	-65	0.00
Capital Expenditures (CapEx)	5.49	1.68	14	21	32	15
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1.97	-6.63	-56	-18	-3.96	0.00
Debt-free Net Working Capital (DFNWC)	143	124	68	382	104	0.00
Net Working Capital (NWC)	143	124	68	382	101	0.00
Net Nonoperating Expense (NNE)	36	49	82	-67	72	8.41
Net Nonoperating Obligations (NNO)	-28	-15	-58	-390	-65	0.00
Total Depreciation and Amortization (D&A)	22	34	59	22	12	6.41
Debt-free, Cash-free Net Working Capital to Revenue	0.64%	-3.27%	-23.69%	-8.63%	-2.21%	0.00%
Debt-free Net Working Capital to Revenue	46.87%	60.98%	29.11%	180.15%	58.09%	0.00%
Net Working Capital to Revenue	46.87%	60.98%	29.11%	180.15%	56.14%	0.00%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.94)	($7.23)	($53.79)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	26.89M	24.31M	10.24M	0.00	0.00	0.00
Adjusted Diluted Earnings per Share	($1.94)	($7.23)	($53.79)	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	26.89M	24.31M	10.24M	0.00	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	28.07M	26.05M	24.19M	0.00	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-16	-119	-320	-312	-169	-21
Normalized NOPAT Margin	-5.32%	-58.81%	-136.46%	-147.18%	-94.46%	-10.85%
Pre Tax Income Margin	-17.23%	-87.23%	-254.81%	-115.64%	-134.58%	-15.14%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-896.95	-85.59	-96.76	-38.20
NOPAT to Interest Expense	0.00	0.00	-701.74	-110.16	-68.47	-27.19
EBIT Less CapEx to Interest Expense	0.00	0.00	-918.45	-92.92	-109.68	-57.94
NOPAT Less CapEx to Interest Expense	0.00	0.00	-723.24	-117.49	-81.39	-46.93
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	-21.09%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-21.09%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from GeneDx's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	39.56%	66.57%	44.22%	44.77%	44.70%	-6.41%	-35.96%	34.66%	-20.03%	6.14%	92.77%
EBITDA Growth	101.63%	157.54%	95.44%	38.26%	72.41%	92.62%	48.16%	69.95%	25.25%	-717.40%	-272.86%
EBIT Growth	72.41%	123.17%	82.73%	40.68%	67.72%	91.46%	44.10%	64.30%	19.73%	-682.29%	-333.13%
NOPAT Growth	66.68%	149.28%	81.89%	79.51%	77.37%	92.11%	52.69%	68.26%	32.41%	-180.60%	27.98%
Net Income Growth	67.74%	121.10%	80.34%	37.56%	66.82%	91.65%	45.49%	45.51%	20.69%	-668.35%	-337.03%
EPS Growth	70.51%	118.87%	81.10%	40.22%	74.34%	96.49%	75.60%	78.04%	20.69%	-668.35%	-337.03%
Operating Cash Flow Growth	162.04%	89.34%	89.34%	91.58%	70.46%	53.82%	53.34%	36.79%	31.82%	-24.37%	-24.56%
Free Cash Flow Firm Growth	86.57%	115.38%	-98.02%	-98.95%	76.63%	91.67%	135.89%	179.42%	-193.63%	0.00%	-241.98%
Invested Capital Growth	0.64%	1.59%	-4.51%	-4.45%	13.04%	8.91%	-52.61%	-50.88%	122.58%	13,472.10%	850.55%
Revenue Q/Q Growth	-8.91%	24.41%	9.02%	12.96%	8.72%	7.72%	9.44%	12.90%	-29.68%	-26.29%	130.13%
EBITDA Q/Q Growth	-97.98%	835.35%	93.17%	-60.62%	24.26%	41.78%	7.48%	28.22%	80.92%	-309.15%	46.37%
EBIT Q/Q Growth	-189.04%	181.32%	73.60%	-44.34%	21.75%	39.38%	9.33%	21.46%	80.23%	-296.99%	42.09%
NOPAT Q/Q Growth	-136.02%	262.41%	26.46%	22.55%	46.73%	40.32%	16.77%	14.48%	81.42%	-257.74%	44.16%
Net Income Q/Q Growth	-220.06%	165.42%	71.51%	-44.14%	21.47%	39.05%	9.49%	23.40%	80.25%	-297.99%	9.52%
EPS Q/Q Growth	-215.00%	164.52%	71.82%	-41.03%	26.42%	35.37%	10.87%	39.47%	80.25%	-297.99%	9.52%
Operating Cash Flow Q/Q Growth	419.89%	27.58%	2.44%	72.55%	45.03%	27.58%	22.94%	3.71%	14.07%	26.83%	-4.39%
Free Cash Flow Firm Q/Q Growth	-182.90%	35.74%	110.31%	105.67%	5.04%	-117.45%	12.22%	225.67%	66.14%	24.86%	-148.36%
Invested Capital Q/Q Growth	-3.20%	8.21%	0.15%	-4.07%	-2.28%	1.71%	0.21%	13.49%	-5.85%	-55.74%	3.87%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	67.13%	69.22%	62.22%	60.91%	59.93%	53.56%	47.39%	38.51%	35.32%	-26.61%	16.28%
EBITDA Margin	0.27%	12.20%	-2.06%	-32.97%	-23.19%	-35.32%	-65.36%	-77.31%	-121.62%	-448.19%	-80.74%
Operating Margin	-5.22%	9.21%	-10.12%	-15.00%	-21.88%	-44.66%	-80.61%	-105.99%	-139.93%	-529.56%	-109.11%
EBIT Margin	-6.25%	6.39%	-9.78%	-40.37%	-31.60%	-45.94%	-81.63%	-98.53%	-141.64%	-503.67%	-93.51%
Profit (Net Income) Margin	-7.49%	5.69%	-10.81%	-41.37%	-32.42%	-44.89%	-79.33%	-95.92%	-141.38%	-503.28%	-93.21%
Tax Burden Percent	107.35%	100.44%	99.44%	99.35%	99.60%	98.43%	99.59%	99.58%	99.76%	100.03%	99.92%
Interest Burden Percent	111.76%	88.58%	111.22%	103.14%	103.03%	99.27%	97.58%	97.76%	100.06%	99.89%	99.76%
Effective Tax Rate	0.00%	-0.44%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-5.77%	13.13%	-9.23%	-12.49%	-17.29%	-30.93%	-35.70%	-55.17%	-163.98%	-894.27%	-91.97%
ROIC Less NNEP Spread (ROIC-NNEP)	8.76%	29.02%	2.61%	41.55%	-2.30%	-9.25%	-20.69%	-48.05%	-154.38%	-857.89%	-87.04%
Return on Net Nonoperating Assets (RNNOA)	-0.87%	-2.63%	-0.28%	-6.83%	0.61%	1.39%	4.13%	15.32%	91.61%	597.82%	51.96%
Return on Equity (ROE)	-6.64%	10.50%	-9.50%	-19.32%	-16.67%	-29.54%	-31.57%	-39.85%	-72.36%	-296.45%	-40.01%
Cash Return on Invested Capital (CROIC)	-5.35%	-9.13%	-15.06%	-27.19%	-59.91%	-70.26%	-31.51%	-47.93%	-410.30%	-339.15%	0.00%
Operating Return on Assets (OROA)	-4.90%	4.66%	-6.33%	-22.73%	-14.92%	-20.46%	-27.05%	-33.05%	-59.67%	-226.23%	-30.18%
Return on Assets (ROA)	-5.88%	4.14%	-7.00%	-23.29%	-15.31%	-19.99%	-26.29%	-32.18%	-59.56%	-226.05%	-30.08%
Return on Common Equity (ROCE)	-6.64%	10.50%	-9.50%	-19.32%	-16.67%	-29.54%	-31.57%	-39.85%	-72.36%	-296.45%	-40.01%
Return on Equity Simple (ROE_SIMPLE)	-14.99%	0.00%	-40.83%	-60.54%	-65.16%	0.00%	-180.43%	-166.85%	-162.29%	0.00%	-49.96%
Net Operating Profit after Tax (NOPAT)	-3.19	8.85	-5.45	-7.41	-9.56	-18	-30	-36	-42	-227	-64
NOPAT Margin	-3.66%	9.25%	-7.08%	-10.50%	-15.32%	-31.26%	-56.43%	-74.19%	-97.95%	-370.69%	-76.38%
Net Nonoperating Expense Percent (NNEP)	-14.52%	-15.89%	-11.84%	-54.04%	-14.99%	-21.67%	-15.01%	-7.12%	-9.60%	-36.38%	-4.93%
Return On Investment Capital (ROIC_SIMPLE)	-0.86%	2.47%	-	-	-	-5.22%	-	-	-	-	-
Cost of Revenue to Revenue	32.87%	30.78%	37.78%	39.09%	40.07%	46.44%	52.61%	61.49%	64.68%	126.61%	83.72%
SG&A Expenses to Revenue	36.89%	28.60%	34.01%	35.70%	35.96%	46.37%	48.96%	76.67%	101.27%	70.43%	66.00%
R&D to Revenue	14.44%	12.12%	15.17%	15.46%	18.53%	21.33%	26.81%	35.19%	33.83%	39.72%	16.04%
Operating Expenses to Revenue	72.35%	60.02%	72.34%	75.92%	81.82%	98.22%	128.00%	144.50%	175.25%	502.94%	125.39%
Earnings before Interest and Taxes (EBIT)	-5.44	6.11	-7.52	-28	-20	-26	-44	-48	-61	-309	-78
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	0.24	12	-1.59	-23	-14	-20	-35	-38	-52	-275	-67
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	9.66	8.61	5.59	3.52	1.14	0.31	0.37	0.52	0.89	0.40	0.60
Price to Tangible Book Value (P/TBV)	24.30	24.37	26.96	24.04	6.20	1.29	1.20	1.31	2.00	1.52	1.76
Price to Revenue (P/Rev)	7.53	6.91	4.28	2.80	1.07	0.35	0.45	0.65	1.30	0.43	1.45
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	11.61	9.60	5.68	3.44	1.14	0.27	0.24	0.31	0.80	0.23	0.49
Enterprise Value to Revenue (EV/Rev)	7.39	6.82	4.26	2.83	1.07	0.28	0.24	0.28	0.66	0.19	0.93
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.43	0.46	0.55	0.58	0.55	0.51	0.28	0.24	0.21	0.26	0.13
Long-Term Debt to Equity	0.43	0.46	0.55	0.58	0.55	0.51	0.28	0.24	0.21	0.26	0.13
Financial Leverage	-0.10	-0.09	-0.11	-0.16	-0.27	-0.15	-0.20	-0.32	-0.59	-0.70	-0.60
Leverage Ratio	1.81	1.77	1.80	1.77	1.75	1.89	1.53	1.51	1.62	1.63	1.50
Compound Leverage Factor	2.02	1.57	2.00	1.82	1.81	1.87	1.49	1.48	1.62	1.63	1.50
Debt to Total Capital	30.26%	31.51%	35.47%	36.79%	35.55%	33.65%	21.57%	19.12%	17.59%	20.71%	11.51%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	30.26%	31.51%	35.47%	36.79%	35.55%	33.65%	21.57%	19.12%	17.59%	20.71%	11.51%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	69.74%	68.49%	64.53%	63.21%	64.45%	66.35%	78.43%	80.88%	82.41%	79.29%	88.49%
Debt to EBITDA	-8.64	-4.08	-1.92	-1.23	-1.08	-0.80	-0.17	-0.16	-0.13	-0.12	-0.25
Net Debt to EBITDA	3.67	1.03	0.07	-0.07	-0.01	0.10	0.11	0.20	0.28	0.11	0.40
Long-Term Debt to EBITDA	-8.64	-4.08	-1.92	-1.23	-1.08	-0.80	-0.17	-0.16	-0.13	-0.12	-0.25
Debt to NOPAT	-11.32	-6.94	-2.78	-1.74	-1.22	-0.91	-0.21	-0.19	-0.16	-0.14	-0.23
Net Debt to NOPAT	4.81	1.74	0.10	-0.09	-0.02	0.11	0.13	0.23	0.32	0.12	0.37
Long-Term Debt to NOPAT	-11.32	-6.94	-2.78	-1.74	-1.22	-0.91	-0.21	-0.19	-0.16	-0.14	-0.23
Altman Z-Score	4.75	3.95	-0.38	-2.08	-3.19	-3.49	-3.48	-2.62	-1.86	-4.38	-0.45
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.25	3.61	2.41	2.38	3.22	3.10	2.51	2.53	2.29	1.47	1.89
Quick Ratio	2.95	3.26	2.00	1.95	2.80	2.77	2.15	2.26	1.98	1.16	1.45
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-4.51	5.45	4.01	1.91	-34	-35	203	181	-144	-425	-566
Operating Cash Flow to CapEx	166.13%	-104.36%	-680.34%	-333.21%	-3,704.97%	-1,339.52%	0.00%	-1,937.74%	-12,025.97%	-2,278.15%	-2,065.50%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	-56.33	0.00	0.00	0.00	-4,111.37	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	-27.49	0.00	0.00	0.00	-1,587.43	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-28.23	0.00	0.00	0.00	-1,600.63	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.79	0.73	0.65	0.56	0.47	0.45	0.33	0.34	0.42	0.45	0.32
Accounts Receivable Turnover	8.81	8.67	7.54	8.11	7.10	5.32	5.42	5.85	6.28	6.71	7.05
Inventory Turnover	9.45	11.43	10.76	9.82	9.16	10.03	6.11	7.72	9.91	11.10	6.49
Fixed Asset Turnover	9.76	9.35	7.95	6.53	5.49	4.82	3.44	3.56	4.05	4.11	3.19
Accounts Payable Turnover	3.09	3.29	2.27	2.01	2.06	1.84	2.56	2.37	3.29	3.96	3.67
Days Sales Outstanding (DSO)	41.41	42.09	48.41	45.01	51.39	68.61	67.41	62.38	58.13	54.36	51.74
Days Inventory Outstanding (DIO)	38.63	31.93	33.91	37.18	39.85	36.39	59.72	47.25	36.84	32.89	56.27
Days Payable Outstanding (DPO)	118.19	110.93	160.60	181.56	177.42	198.35	142.35	153.85	110.79	92.28	99.49
Cash Conversion Cycle (CCC)	-38.15	-36.91	-78.28	-99.37	-86.17	-93.35	-15.23	-44.22	-15.82	-5.03	8.52
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	210	217	200	200	209	213	210	209	185	196	443
Invested Capital Turnover	1.58	1.42	1.30	1.19	1.13	0.99	0.63	0.74	1.67	2.41	1.20
Increase / (Decrease) in Invested Capital	1.33	3.40	-9.46	-9.31	24	17	-233	-217	102	198	502
Enterprise Value (EV)	2,438	2,083	1,139	689	238	57	49	66	147	44	216
Market Capitalization	2,486	2,111	1,143	683	236	71	94	153	291	102	334
Book Value per Share	$9.17	$8.93	$7.59	$7.42	$7.95	$8.81	$9.87	$11.57	$0.41	$0.66	$1.47
Tangible Book Value per Share	$3.65	$3.15	$1.57	$1.09	$1.46	$2.14	$3.03	$4.55	$0.18	$0.17	$0.50
Total Capital	369	358	317	307	322	344	324	366	399	320	634
Total Debt	112	113	112	113	114	116	70	70	70	66	73
Total Long-Term Debt	112	113	112	113	114	116	70	70	70	66	73
Net Debt	-47	-28	-4.06	6.10	1.41	-15	-44	-87	-144	-58	-118
Capital Expenditures (CapEx)	6.13	3.05	0.65	1.35	0.44	2.23	-0.14	2.76	0.46	2.84	4.28
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2.89	1.97	-7.79	-13	-0.22	-6.63	-11	-28	-61	-56	-47
Debt-free Net Working Capital (DFNWC)	156	143	109	94	113	124	103	129	153	68	144
Net Working Capital (NWC)	156	143	109	94	113	124	103	129	153	68	144
Net Nonoperating Expense (NNE)	3.34	3.41	2.87	22	11	7.82	12	11	19	81	14
Net Nonoperating Obligations (NNO)	-47	-28	-4.06	6.10	1.41	-15	-44	-87	-144	-58	-118
Total Depreciation and Amortization (D&A)	5.68	5.56	5.93	5.22	5.25	6.09	8.67	10	8.64	34	11
Debt-free, Cash-free Net Working Capital to Revenue	-0.87%	0.64%	-2.92%	-5.32%	-0.10%	-3.27%	-5.25%	-11.74%	-27.12%	-23.69%	-20.37%
Debt-free Net Working Capital to Revenue	47.34%	46.87%	40.66%	38.54%	50.80%	60.98%	50.10%	54.52%	68.48%	29.11%	62.42%
Net Working Capital to Revenue	47.34%	46.87%	40.66%	38.54%	50.80%	60.98%	50.10%	54.52%	68.48%	29.11%	62.42%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.23)	$0.20	($0.31)	($1.10)	($0.78)	($1.06)	($1.64)	($1.84)	($3.04)	($995.28)	($6.60)
Adjusted Weighted Average Basic Shares Outstanding	28.15M	26.89M	27.10M	26.62M	26.06M	24.31M	25.79M	25.42M	20.06M	310.21K	11.54M
Adjusted Diluted Earnings per Share	($0.23)	$0.20	($0.31)	($1.10)	($0.78)	($1.06)	($1.64)	($1.84)	($3.04)	($995.28)	($6.60)
Adjusted Weighted Average Diluted Shares Outstanding	28.15M	26.89M	27.10M	26.62M	26.06M	24.31M	25.79M	25.42M	20.06M	310.21K	11.54M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.20	$0.00	$0.00	$0.00	($1.06)	$0.00	$0.00	$0.00	($995.28)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	28.53M	28.07M	27.47M	26.94M	26.14M	26.05M	25.88M	25.77M	25.59M	24.19M	11.72M
Normalized Net Operating Profit after Tax (NOPAT)	-3.19	6.16	-5.45	-7.41	-9.56	-18	-24	-36	-41	-80	-64
Normalized NOPAT Margin	-3.66%	6.45%	-7.08%	-10.50%	-15.32%	-31.26%	-45.55%	-74.19%	-94.51%	-130.91%	-76.38%
Pre Tax Income Margin	-6.98%	5.66%	-10.87%	-41.64%	-32.55%	-45.60%	-79.65%	-96.32%	-141.72%	-503.13%	-93.29%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	-33.04	0.00	0.00	0.00	-1,745.74	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	-16.02	0.00	0.00	0.00	-1,207.28	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-33.78	0.00	0.00	0.00	-1,758.94	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-16.76	0.00	0.00	0.00	-1,220.48	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About GeneDx's Financials

When does GeneDx's fiscal year end?

According to the most recent income statement we have on file, GeneDx's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has GeneDx's net income changed over the last 5 years?

GeneDx's net income appears to be on an upward trend, with a most recent value of -$52.29 million in 2024, rising from -$29.70 million in 2019. The previous period was -$175.77 million in 2023.

What is GeneDx's operating income?

GeneDx's total operating income in 2024 was -$23.21 million, based on the following breakdown:

Total Gross Profit: $194.40 million
Total Operating Expenses: $217.61 million

How has GeneDx revenue changed over the last 5 years?

Over the last 5 years, GeneDx's total revenue changed from $196.17 million in 2019 to $305.45 million in 2024, a change of 55.7%.

How much debt does GeneDx have?

GeneDx's total liabilities were at $174.13 million at the end of 2024, a 8.7% decrease from 2023, and a 29.6% decrease since 2020.

How much cash does GeneDx have?

In the past 4 years, GeneDx's cash and equivalents has ranged from $85.21 million in 2024 to $400.57 million in 2021, and is currently $85.21 million as of their latest financial filing in 2024.

How has GeneDx's book value per share changed over the last 5 years?

Over the last 5 years, GeneDx's book value per share changed from 0.00 in 2019 to 8.93 in 2024, a change of 892.7%.

Related Companies

This page (NASDAQ:WGSWW) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeneDx (WGSWW) Financials

Frequently Asked Questions About GeneDx's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GeneDx (WGSWW) Financials

Annual Income Statements for GeneDx

Quarterly Income Statements for GeneDx

Annual Cash Flow Statements for GeneDx

Quarterly Cash Flow Statements for GeneDx

Annual Balance Sheets for GeneDx

Quarterly Balance Sheets for GeneDx

Annual Metrics And Ratios for GeneDx

Quarterly Metrics And Ratios for GeneDx

Frequently Asked Questions About GeneDx's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools